ArticlePancreas2026
Knockdown of Lymphoid Enhancer-binding Factor 1 Inhibits Pancreatic Adenocarcinoma Growth and Neoangiogenesis by Curbing Notch1 and Nuclear Factor Kappa B Signaling Pathways.
Article in Pancreas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the impaction of LEF1 for malignant development of pancreatic adenocarcinoma (PAAD) and its specific mechanisms. MATERIALS AND
methodsThe expression of LEF1 in PAAD and normal tissues was inspected by bioinformatics, qRT-PCR, and western blot (WB). AsPC-1 and BxPC-3 were selected for further knockdown study. The post-knockdown cellular malignant progression was evaluated by CCK-8, EdU, clonogenic assay, wound healing, Transwell, Calcein AM/PI staining, and LDH release assays. Conditioned medium (CM) of PAAD after LEF1 knockdown was collected to culture HUVEC for evaluating the effect on angiogenesis. Immunofluorescence assay and WB were employed to detect the changes of Notch1 and NF-κB pathway. Finally, a nude mouse tumor xenograft model was established to verify the in vivo suppressive effect of knocking down LEF1 on PAAD.
resultsLEF1 is highly expressed in PAAD. The proliferation, migration, and invasion of AsPC-1/sh-LEF1 and BxPC-3/sh-LEF1 were inhibited, and the apoptosis was significantly increased. The CM of AsPC-1/sh-LEF1 and BxPC-3/sh-LEF1 significantly inhibited HUVEC migration and angiogenesis. The intranuclear expression of Notch1, NICD, Hes1, and P65 proteins were reduced, indicating that LEF1 downregulation inhibited the activation of the Notch1 and NF-κB. Finally, the inhibitory effect of LEF1 downregulation on PAAD growth was further verified in vivo, confirming the important role of LEF1 in PAAD development.
conclusionsKnockdown of LEF1 can inhibit the growth and neoangiogenesis of PAAD by inhibiting Notch1 and NF-κB, thus inhibiting the malignant progression of PAAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.